TKPHF — TAKEDA PHARMACEUTICAL CO LTD
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1395064 ·
Last close
$37.00
Market Cap
$59.08B
52W High
$37.82
52W Low
$25.40
ADV30
1,277
Next earnings
2026-10-29
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 1,219,900,000,000 | 813,224,000,000 | 201,417,000,000 | 113,197,000,000 | 15,663,271,000,000 | 460,982,000,000 | 8,104,395,000,000 |
| Mar 2026 | 1,094,541,000,000 | 688,837,000,000 | 42,068,000,000 | -368,471,000,000 | 15,511,506,000,000 | 595,054,000,000 | 8,080,857,000,000 |
| Dec 2025 | 1,191,698,000,000 | 790,550,000,000 | 168,822,000,000 | 103,640,000,000 | 15,408,774,000,000 | 654,937,000,000 | 7,764,684,000,000 |
| Sep 2025 | 1,112,796,000,000 | 732,735,000,000 | 68,996,000,000 | -11,802,000,000 | 14,470,300,000,000 | 681,486,000,000 | 7,338,611,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$1,041,432,000,000
Investing CF
$-369,141,000,000
Financing CF
$-496,819,000,000
CapEx
$-414,659,000,000
Dividends Paid
$-311,901,000,000
Buybacks
$-51,603,000,000
EPS Diluted TTM
$148.77
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$667,007,000,000
Inventory
$1,447,259,000,000
Receivables
$956,140,000,000
ST Investments
$66,600,000,000
EBIT TTM
$-25,457,000,000
Pretax Income TTM
$-130,267,000,000
Interest Exp TTM
$104,810,000,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$4,618,934,812,672
EBITDA
$1,249,335,967,744
Free Cash Flow
$541,443,883,008
Enterprise Value
$5,133,704,888,320
Total Cash
$460,981,993,472
Total Debt
$5,536,499,105,792
Shares Out
1,596,751,439
Trailing EPS
$-0.68
Book Value
$31.13
ROE
-2.3%
ROA
2.7%
Div Yield
3.58%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 4,505,720,000,000 | 464,451,000,000 | -152,390,000,000 | 15,511,506,000,000 | 8,080,857,000,000 | 7,429,441,000,000 | 1,041,431,000,000 |
| Mar 2025 | 4,581,551,000,000 | 466,370,000,000 | 107,928,000,000 | 14,248,344,000,000 | 7,312,365,000,000 | 6,935,084,000,000 | 1,057,182,000,000 |
| Mar 2024 | 4,263,762,000,000 | 309,901,000,000 | 144,067,000,000 | 15,108,792,000,000 | 7,834,787,000,000 | 7,273,264,000,000 | 716,344,000,000 |
| Mar 2023 | 4,027,478,000,000 | 587,812,000,000 | 317,017,000,000 | 13,957,750,000,000 | 7,603,079,000,000 | 6,354,122,000,000 | 977,156,000,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.81
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TAK | TAKEDA PHARMACEUTICAL CO LTD | $58.09B | $18.19 | — |
| TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | $46.15B | $39.60 | — |
| REGN | REGENERON PHARMACEUTICALS, INC. | $76.69B | $758.27 | — |
| ONC | BeOne Medicines Ltd. | $38.16B | $365.94 | — |
| SNYNF | Sanofi | $96.05B | $80.17 | — |
News headlines (Yahoo Finance, 1h cache)
Takeda Pharmaceutical (TSE:4502) Could Be 13% Undervalued On Strong Phase 3 Psoriasis Data
2026-09-30 20:09 · Yahoo
Asian Equities Traded in the US as American Depositary Receipts Rise Modestly in Wednesday Trading
2026-09-30 14:49 · Yahoo
Takeda Reports New Psoriasis Treatment Outperformed Competitor in Phase 3 Trial
2026-09-30 08:12 · Yahoo
Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill
2026-09-30 05:00 · Yahoo
KROS Begins Dosing in Phase II Study With Rinvatercept in DMD
2026-09-29 13:17 · Yahoo
Ginkgo Datapoints and Apheris Welcome AbbVie, argenx, Lundbeck, and Takeda as Founding Members of the Antibody Developability Consortium
2026-09-29 12:00 · Yahoo
Innovent Announces Expansion of Global Phase 3 MarsLight-11 Study of IBI363/TAK-928 (Alpha-biased IL-2/PD-1 Bispecific Fusion Protein) in Immunotherapy-Resistant NSCLC to Include Patients with Non-Squ
2026-09-28 00:00 · Yahoo
Basecamp raises $140M before the clinic; J&J and Compass’ potential rivalry
2026-09-25 12:57 · Yahoo
Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 Arcotatug Tavatecan (TAK-921) Data, at ESMO 2026
2026-09-22 13:30 · Yahoo
Can Sotyktu's Long-Term PsA Data Boost Bristol Myers' Prospects?
2026-09-18 19:17 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.